A chronic infection of the CONJUNCTIVA and CORNEA caused by CHLAMYDIA TRACHOMATIS.
| Excerpt | Reference |
|---|
| "trachomatis serotypes in 32 inclusion positive school children suffering from trachoma." | ( Kumar, VN; Satpathy, G; Sujata, M, 1991) |
| "PCR-EIA detected C trachomatis in 24%, 54%, and 95% of subjects, respectively, compared with elementary body (EB) detection by DFA of 1%, 28%, and 60%, respectively." | ( Bobo, L; Mkocha, H; Munoz, B; Quinn, T; Viscidi, R; West, S, 1991) |
| "trachomatis (TW-5), had a reduction in the percentage of inclusion-containing cells by over 80% in a dose-dependent manner." | ( Byrne, GI; Carlin, JP; Miller, SL; Padilla, ML; Rapoza, PA; Tahija, SG, 1991) |
| "Trachoma is the leading infectious cause of blindness worldwide, and epidemiologic studies of factors that may increase the transmission of ocular Chlamydia trachomatis are needed." | ( Congdon, N; Katala, S; Mele, L; West, SK, 1991) |
| "trachomatis serovars B, C, and E." | ( Taylor, HR, 1990) |
| "trachomatis serovar L1 was used as a probe to locate the 60 kDa CrP gene of a recent serovar B trachoma isolate (Jali 20/OT)." | ( Clarke, IN; Lambden, PR; Ward, ME; Watson, MW, 1989) |
| "trachomatis in the conjunctival epithelium of patients with trachoma." | ( Booth-Mason, S; Mabey, DC, 1986) |
| "Active trachoma is characterized by chronic inflammation of the conjunctiva, and repeated episodes of reinfection are thought to be necessary to sustain this inflammation." | ( Caldwell, HD; Johnson, SL; Prendergast, RA; Schachter, J; Taylor, HR, 1987) |
| "The prevalence of trachoma is lower in pastoralists who herd mainly camels than in pastoralists who herd mainly cattle." | ( De Sole, G, 1987) |
| "In addition, trachoma is aggravated if there are associated bacterial infections and these lead to more frequent corneal complications." | ( Kupka, K; Maxwell-Lyons, F; Nizetic, B; Reinhards, J; Weber, A, 1968) |
| "In areas where trachoma is common special clinics should be established for the treatment and follow-up of patients and contacts." | ( Howells, CH; Johnson, L; Soni, KG; Woodhouse, DF, 1969) |
| "C." | ( Ripa, KT, 1982) |
| "C." | ( Smith, TF; Weed, LA, 1983) |
| "trachomatis correlates well with in vitro activity if sufficient antimicrobial is given for a long enough duration." | ( Bowie, WR, 1982) |
| "trachomatis (serovar C) elementary bodies." | ( Campos, M; O'Brien, TP; Pal, S; Prendergast, RA; Taylor, HR; Whittum-Hudson, JA, 1995) |
| "trachomatis inclusion-formation." | ( Babikir, HE; Elhassan, AE; Fröman, G; Mahmoud, EA; Mårdh, PA, 1994) |
| "Blindness due to trachoma is a serious public health issue world wide." | ( Arullendran, P; Bailey, RL; Mabey, DC; Whittle, HC, 1993) |
| "trachomatis infection." | ( Arullendran, P; Bailey, RL; Mabey, DC; Whittle, HC, 1993) |
| "In conclusion, C." | ( Bobo, L; Mkocha, H; Novak, N; Quinn, TC; Vitale, S; West, S, 1996) |
| "Chlamydia trachomatis is the leading cause worldwide of preventable infectious blindness (trachoma) and sexually transmitted disease, including nongonoccocal urethritis and pelvic inflammatory disease." | ( An, LL; MacDonald, AB; Prendergast, RA; Saltzman, WM; Whittum-Hudson, JA, 1996) |
| "Chlamydia trachomatis consists of two biovars, lymphogranuloma venereum (LGV) and trachoma, that differ in their infectivity in vivo and in vitro." | ( Chen, JC; Stephens, RS, 1997) |
| "trachomatis 5." | ( Imrie, M; McKenzie, H; Norman, J; Penney, GC; Smith, R; Thomson, M; Vale, L, 1998) |
| "Trachoma is the leading cause of preventable blindness." | ( Bailey, R; Bobo, L; Dawson, CR; Faal, H; Mabey, D; Mkocha, H; Quinn, TC; Sallam, S; Schachter, J; Sheta, A; Vitale, S; West, SK, 1999) |
| "trachomatis infection and clinical trachoma in endemic areas and may be an important approach to control of trachoma." | ( Bailey, R; Bobo, L; Dawson, CR; Faal, H; Mabey, D; Mkocha, H; Quinn, TC; Sallam, S; Schachter, J; Sheta, A; Vitale, S; West, SK, 1999) |
| "Trachoma is a leading cause of preventable blindness worldwide." | ( Tabbara, KF, 2001) |
| "Chlamydia trachomatis was suspected in 2." | ( Alió, JL; Ferrer, C; Javaloy, J; Vidal, MT, 2003) |
| "Cicatricial trachoma is more frequent." | ( Alió, JL; Ferrer, C; Javaloy, J; Vidal, MT, 2003) |
| "Clinically active trachoma is not always a reliable marker of infection, particularly in teenagers and after treatment." | ( Bassem, A; Bird, M; Dawson, CR; Lietman, TM; Miao, Y; Osman, A; Schachter, JS; Shama, A, 2003) |
| "Trachoma is an ocular disease caused by repeated infection with Chlamydia trachomatis." | ( Buchan, J; Foster, A; Kuper, H; Mabey, D; Solomon, AW; Zondervan, M, 2003) |
| "Trachoma is the world's leading cause of preventable blindness." | ( Kumaresan, JA; Mecaskey, JW, 2003) |
| "trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian community in which trachoma was endemic." | ( Aguirre, A; Alexander, ND; Bailey, RL; Courtright, P; Foster, A; Holland, MJ; Mabey, DC; Massae, PA; Molina, S; Natividad-Sancho, A; Peeling, RW; Safari, S; Shao, JF; Solomon, AW; West, SK, 2004) |
| "trachomatis infection in the community was 13." | ( Aguirre, A; Alexander, ND; Bailey, RL; Courtright, P; Foster, A; Holland, MJ; Mabey, DC; Massae, PA; Molina, S; Natividad-Sancho, A; Peeling, RW; Safari, S; Shao, JF; Solomon, AW; West, SK, 2004) |
| "trachomatis infection." | ( Aguirre, A; Alexander, ND; Bailey, RL; Courtright, P; Foster, A; Holland, MJ; Mabey, DC; Massae, PA; Molina, S; Natividad-Sancho, A; Peeling, RW; Safari, S; Shao, JF; Solomon, AW; West, SK, 2004) |
| "Trachoma is the most important infectious cause of blindness worldwide." | ( Cumberland, P; Hailu, G; Todd, J, 2005) |
| "trachomatis load (COCTL) which is similar to the community microfilarial load (CMFL) of onchocerciasis." | ( Alexander, ND; Bailey, RL; Foster, A; Holland, MJ; Mabey, DC; Shao, JF; Solomon, AW; West, SK, 2005) |
| "Trachoma is a chronic granular conjunctivitis due to Chlamydia trachomatis serotypes A to C." | ( Labetoulle, M; Raymond, J, 2005) |
| "Trachoma is the leading infectious cause of blindness worldwide." | ( Alemayehu, W; Imeru, A; Melese, M; Munoz, B; West, ES; West, SK, 2005) |
| "Trachoma is a major cause of blindness." | ( Buchan, JC; Foster, A; Kuper, H; Mabey, D; Solomon, AW; Zondervan, M, 2005) |
| "Chlamydia trachomatis ocular and urogenital infections represent major public health problems, whereas Chlamydophila pneumoniae is a common aetiological agent of community-acquired pneumonia." | ( Greub, G; Hammerschlag, MR; Senn, L, 2005) |
| "Trachoma is one of the leading preventable causes of blindness worldwide." | ( Cumberland, P; Edwards, T; Hailu, G; Todd, J, 2006) |
| "Infection with C trachomatis did not differ between groups at 6 months post-treatment (9%vs 7%, p=0." | ( Bailey, R; Emerson, PM; Mabey, D; McHiwa, W; Mkocha, H; Munoz, B; West, SK, 2006) |
| "Trachoma is a neglected disease and also the world's leading infectious cause of blindness." | ( Bailey, R; Burton, M; Emerson, PM; Mabey, D; Solomon, AW, 2006) |
| "Trachoma is the leading infectious cause of blindness." | ( Aguirre, A; Bailey, R; Burton, MJ; Gower, EW; Holland, M; Mabey, DC; Makalo, P; Massae, P; Mkocha, H; Muñoz, B; Solomon, AW; West, SK, 2006) |
| "trachomatis infection are discussed." | ( Behrens-Baumann, W, 2007) |
| "trachomatis were determined in a community 3." | ( Gaydos, C; Mkocha, H; Munoz, B; Quinn, T; West, SK, 2007) |
| "trachomatis infection were not eliminated in this trachoma hyperendemic village 3." | ( Gaydos, C; Mkocha, H; Munoz, B; Quinn, T; West, SK, 2007) |
| "In conclusion, trachoma is a common disease of public-health importance only in the low- and mid-altitude villages in the Gurage zone, where there are large numbers of eye-seeking flies, and not in the villages that lie >3000 m above sea level, where there is a dearth of such flies." | ( Alemayehu, W; Asfaw, T; Geyid, A; Mekonnen, Y; Melese, M; Taye, A; Tilahun, D, 2007) |
| "trachomatis transmission were assessed." | ( Courtenay, O; Favacho, J; Garcez, LM; Reilly, LA, 2007) |
| "trachomatis by polymerase chain reaction." | ( Andreason, A; Cumberland, P; Edwards, T; Hailu, G; Harding-Esch, EM; Mabey, DC; Todd, J, 2008) |
| "Odds of C." | ( Andreason, A; Cumberland, P; Edwards, T; Hailu, G; Harding-Esch, EM; Mabey, DC; Todd, J, 2008) |
| "trachomatis and active trachoma were identified." | ( Andreason, A; Cumberland, P; Edwards, T; Hailu, G; Harding-Esch, EM; Mabey, DC; Todd, J, 2008) |
| "trachomatis DNA." | ( Andreasen, A; Cumberland, P; Edwards, T; Hailu, G; Harding-Esch, E; Mabey, D; Todd, J, 2008) |
| "trachomatis infection was only 0." | ( Aryee, EA; Bailey, RL; Edwards, T; Harding-Esch, EM; Holland, MJ; Mabey, DC; Sarr-Sissoho, I; Sillah, A; Snell, P, 2008) |
| "trachomatis in children in a hyperendemic village in Tanzania." | ( Mkocha, H; Muñoz, BE; West, SK; Wolle, MA, 2009) |
| "The prevalence of trachoma is high." | ( Goyol, M; Mpyet, C; Ogoshi, C, 2010) |
| "Trachoma is the leading infectious cause of blindness." | ( Alemayehu, W; Gaynor, BD; Halfpenny, C; Hong, KC; House, J; Keenan, JD; Lakew, T; Lietman, TM; Porco, TC; Shah, NA; Whitcher, JP, 2010) |
| "Trachoma is the commonest infectious cause of blindness." | ( Bailey, RL; Burton, MJ; Harding-Esch, EM; Hu, VH; Kadimpeul, J; Mabey, DC, 2010) |
| "Infection with C." | ( Abdou, A; Baarè, I; Kadri, B; Moussa, F; Munoz, BE; Nassirou, B; Opong, E; Riverson, J; West, SK, 2010) |
| "trachomatis infection in endemic communities in Niger." | ( Abdou, A; Baarè, I; Kadri, B; Moussa, F; Munoz, BE; Nassirou, B; Opong, E; Riverson, J; West, SK, 2010) |
| "Trachoma is the leading infectious cause of blindness." | ( Bailey, RL; Burton, MJ; Holland, MJ; Mabey, DC; Makalo, P; Rajak, SN; Sillah, A, 2010) |
| "trachomatis were collected at baseline, 6 months, and 1 year." | ( Bailey, RL; Burton, MJ; Holland, MJ; Mabey, DC; Makalo, P; Rajak, SN; Sillah, A, 2010) |
| "Trachoma is a major cause of blindness in the developing world and 63 million people are currently infected." | ( Basáñez, MG; Blake, IM; Gambhir, M; Grassly, NC, 2010) |
| "trachomatis infection in randomly selected children aged 0-5 years from 48 Gambian and 36 Tanzanian communities." | ( Bailey, RL; Burr, SE; Edwards, T; Gaydos, CA; Harding-Esch, EM; Holland, MJ; Mabey, DC; Mkocha, H; Munoz, B; Sillah, A; Stare, D; West, SK, 2010) |
| "trachomatis infection in this setting." | ( Bailey, RL; Burr, SE; Edwards, T; Gaydos, CA; Harding-Esch, EM; Holland, MJ; Mabey, DC; Mkocha, H; Munoz, B; Sillah, A; Stare, D; West, SK, 2010) |
| "Trachoma is the principal cause of infectious blindness." | ( Bailey, R; Gaydos, C; Harding-Esch, E; Holland, M; Mabey, D; Munoz, B; Stare, D; West, S, 2011) |
| "Trachoma is the world's leading infectious cause of blindness." | ( Evans, JR; Solomon, AW, 2011) |
| "Trachoma is the leading infectious cause of blindness in the world, and for endemic communities, mass treatment with azithromycin reduces the pool of infection." | ( Cajas-Monson, LC; Gaydos, CA; Mkocha, H; Muñoz, B; Quinn, TC; West, SK, 2011) |
| "trachomatis infection." | ( Gaydos, CA; Mkocha, H; Munoz, B; Quinn, TC; West, SK, 2011) |
| "trachomatis infection were related to the extent of the previous year's azithromycin coverage." | ( Gaydos, CA; Mkocha, H; Munoz, B; Quinn, TC; West, SK, 2011) |
| "trachomatis at baseline, and 6 months after mass drug administration." | ( Gaydos, C; Mkocha, H; Munoz, B; Quinn, TC; Stare, D; West, SK, 2011) |
| "trachomatis by Amplicor Polymerase Chain Reaction." | ( Andreasen, AA; Bailey, RL; Edwards, T; Harding, EF; Harding-Esch, EM; Holland, MJ; Mabey, DC; Molina, S; Roberts, Ch; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2011) |
| "trachomatis as its specificity decreases in hot and dry conditions: the environment in which trachoma is predominantly found." | ( Andreasen, AA; Bailey, RL; Edwards, T; Harding, EF; Harding-Esch, EM; Holland, MJ; Mabey, DC; Molina, S; Roberts, Ch; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2011) |
| "Surgery for trachoma is more cost effective than extra-capsular cataract surgery and can reverse trichiasis (in-growing eyelashes), but needs to be repeated every few years." | ( Baneke, A, 2012) |
| "Anti-Chlamydial trachomatis (anti-CT) responses, particularly anti-heat shock 60 (Hsp60), antibodies confer a higher risk of ectopic pregnancy." | ( Daponte, A; Deligeoroglou, E; Messinis, IE; Pournaras, S; Skentou, H, 2012) |
| "Trachoma is the leading cause of preventable blindness worldwide." | ( Ketema, K; Muluye, D; Tiruneh, M; Woldeyohannes, D, 2012) |
| "Active trachoma is a major public problem among 1-9 years children and significantly associated with a number of risky factors." | ( Ketema, K; Muluye, D; Tiruneh, M; Woldeyohannes, D, 2012) |
| "Chlamydia trachomatis is a gram-negative bacterium that infects the columnar epithelium of the cervix, urethra, and rectum, as well as nongenital sites such as the lungs and eyes." | ( McClaskey, EL; Mishori, R; WinklerPrins, VJ, 2012) |
| "The prevalence of C trachomatis at 18 months." | ( Bailey, R; Gaydos, CA; Lietman, TA; Mkocha, H; Munoz, B; Quinn, T; West, SK; Yohannan, J, 2013) |
| "Infection with C trachomatis in communities with average trachoma rates at 12% to 13% cannot be eliminated before 3 rounds of MDA with azithromycin." | ( Bailey, R; Gaydos, CA; Lietman, TA; Mkocha, H; Munoz, B; Quinn, T; West, SK; Yohannan, J, 2013) |
| "Trachoma is a public health problem in Ethiopia accounting for 35-50% of cases of blindness." | ( Jemaneh, AA; Mekonnen, MG; Yalew, KN, 2012) |
| "trachomatis infection." | ( Bailey, RL; Basáñez, MG; Blake, IM; Burton, MJ; Donnelly, CA; Gambhir, M; Grassly, NC; Koukounari, A; Mabey, DC; Moustaki, I; Solomon, AW, 2013) |
| "Trachoma is the leading cause of infectious blindness worldwide." | ( Ejigu, M; Gelaw, Y; Ilako, DR; Kariuki, MM, 2013) |
| "Trachoma is endemic in Kersa District with active trachoma being a public health problem in the studied sub-districts." | ( Ejigu, M; Gelaw, Y; Ilako, DR; Kariuki, MM, 2013) |
| "Trachoma is the leading cause of infectious blindness worldwide." | ( Palmer, SL; Stauber, C; Strasser, S; Travers, A, 2013) |
| "trachomatis infection was less than 5%." | ( Bailey, R; Edwards, T; Gaydos, C; Lietman, T; Mabey, D; Mkocha, H; Munoz, B; Porco, T; Quinn, TC; West, SK, 2013) |
| "Chlamydia trachomatis isolates were obtained before and after MDA in 15 paired samples and were tested for antimicrobial susceptibility." | ( Gaydos, CA; Hardick, J; Mkocha, H; Moncada, J; Munoz, B; Quinn, TC; Schachter, J; Storey, P; West, SK, 2014) |
| "Trachoma is the world's leading cause of infectious blindness." | ( Addiss, DG; Freeman, MC; Haddad, D; McGuire, C; Ogden, S; Stocks, ME, 2014) |
| "trachomatis infection (OR 0." | ( Addiss, DG; Freeman, MC; Haddad, D; McGuire, C; Ogden, S; Stocks, ME, 2014) |
| "trachomatis infection and TF were assessed in 3,200 randomly sampled children aged five years and younger, who were examined prior to each MDA." | ( Gaydos, CA; Lee, JS; Mkocha, H; Muñoz, BE; Quinn, TC; West, SK, 2014) |
| "trachomatis infection and TF weakened in children with each MDA, as both infection and clinical disease prevalence declined." | ( Gaydos, CA; Lee, JS; Mkocha, H; Muñoz, BE; Quinn, TC; West, SK, 2014) |
| "trachomatis DNA and antibody responses for IgA and total IgG were measured in dried bloods spots." | ( Dize, L; Gaydos, C; Goodhew, EB; Lammie, PJ; Martin, DL; Mkocha, H; Morgan, SM; Munoz, B; Switzer, AJ; West, SK; Wiegand, RE, 2014) |
| "trachomatis infection in the differential diagnosis of acute or chronic follicular conjunctivitis among sexually active young individuals." | ( Carvalho, AC; Franzoni, A; Gargiulo, F; Matteelli, A; Sulis, G; Urbinati, L, 2014) |
| "Chlamydia trachomatis is an obligate intracellular epitheliotropic bacterial pathogen of humans." | ( Caldwell, HD; Carlson, JH; Kanakabandi, K; Porcella, SF; Song, L; Sturdevant, DE; Sturdevant, GL; Virtaneva, K; Whitmire, WM; Wilder, H, 2015) |
| "Blinding trachoma is targeted for elimination by 2020 using the SAFE strategy (Surgery, Antibiotics, Facial cleanliness, and Environmental improvements)." | ( Emerson, PM; Gelderblom, HC; Haddad, D; Jimenez, V; Mann Flueckiger, R, 2015) |
| "Trachoma is the leading infectious cause of blindness worldwide." | ( Berhe, R; Gedefaw, M; Nigusie, A, 2015) |
| "Trachoma is targeted for elimination by 2020." | ( Black, CM; Dize, L; Gambhir, M; Gaydos, CA; Goodhew, B; Kasubi, M; Lammie, P; Martin, DL; Mkocha, H; West, S; Wiegand, R, 2015) |
| "Trachoma is a blinding disease caused by conjunctival infection with Chlamydia trachomatis (Ct)." | ( Bailey, RL; Cassama, E; Derrick, T; Holland, MJ; Last, AR; Markham-David, R; Marks, M; Nabicassa, M, 2016) |
| "Active trachoma is caused by chronic infection of the conjunctiva by Chlamydia trachomatis, and is the world's leading infectious cause of blindness." | ( Lansingh, VC, 2016) |
| "Chlamydia trachomatis is the most common bacterial sexually transmitted infection and is frequently asymptomatic; ocular C." | ( Bottomley, C; Butcher, R; Kako, H; Mabey, DC; Marks, M; Pitakaka, R; Sokana, O; Solomon, AW; Tome, H, 2016) |
| "trachomatis and Neisseria gonorrhoeae using the BD Probetec strand displacement assay." | ( Bottomley, C; Butcher, R; Kako, H; Mabey, DC; Marks, M; Pitakaka, R; Sokana, O; Solomon, AW; Tome, H, 2016) |
| "C." | ( Bottomley, C; Butcher, R; Kako, H; Mabey, DC; Marks, M; Pitakaka, R; Sokana, O; Solomon, AW; Tome, H, 2016) |
| "trachomatis infection following azithromycin MDA for trachoma elimination." | ( Bottomley, C; Butcher, R; Kako, H; Mabey, DC; Marks, M; Pitakaka, R; Sokana, O; Solomon, AW; Tome, H, 2016) |
| "Trachoma is the leading infectious cause of blindness and is caused by ocular infection with the bacterium Chlamydia trachomatis (Ct)." | ( Alexander, N; Butcher, R; Cikamatana, L; Kama, M; Mabey, DC; Macleod, CK; Mudaliar, U; Natutusau, K; Pavluck, AL; Rafai, E; Roberts, CH; Solomon, AW; Willis, R, 2016) |
| "Both yaws and trachoma are endemic in the Pacific." | ( Bottomley, C; Kilua, G; Mabey, DC; Marks, M; Nachamkin, E; Pillay, A; Puiahi, E; Sokana, O; Solomon, AW, 2016) |
| "Trachoma is a serious public health problem in rural Ethiopia." | ( Bekele, Z; Muluneh, EK; Zewotir, T, 2016) |
| "trachomatis infection." | ( Dize, L; Dreger, K; Ervin, AM; Gaydos, C; Mkocha, H; Munoz, B; Quinn, TC; West, SK, 2016) |
| "trachomatis were equivalent between the two arms (5." | ( Dize, L; Dreger, K; Ervin, AM; Gaydos, C; Mkocha, H; Munoz, B; Quinn, TC; West, SK, 2016) |
| "trachomatis B to infect human conjunctival epithelial cells (HCjE) and studied the effects of wIRA on non-infected ocular structures with two ex vivo eye models." | ( Barisani-Asenbauer, T; Blenn, C; Borel, N; Frohns, A; Frohns, F; Leonard, CA; Marti, H; Rahn, C; Stein, E, 2016) |
| "Trachoma is a public health issue in PNG." | ( Burnett, A; Garap, J; Keys, D; Ko, R; Macleod, C; Pahau, D; Sokana, O; Solomon, AW; Wabulembo, G; Willis, R, 2016) |
| "The prevalence of trachoma is relatively low in most of Niger State." | ( Adamu, MD; Bosso, UA; Chu, BK; Flueckiger, RM; Isiyaku, S; Mpyet, C; Muazu, H; Muhammad, N; Nwobi, BC; Olamiju, F; Olobio, N; Onyebuchi, U; Pavluck, A; Solomon, AW; Umar, MM; William, A; Willis, R, 2016) |
| "Trachoma is a major cause of blindness in Ethiopia, and targeted for elimination as a public health problem by the year 2020." | ( Abashawl, A; Adamu, L; Adamu, Y; Chu, BK; Dejene, M; Fikru, W; Flueckiger, RM; Kidu, B; Macleod, C; Pavluck, AL; Solomon, AW; Willis, R, 2016) |
| "Active trachoma is prevalent in the Solomon Islands." | ( Butcher, R; Chu, BK; Jack, K; Macleod, C; Marks, M; Posala, C; Sokana, O; Solomon, AW; Willis, R, 2016) |
| "trachomatis urogenital serotypes (D-K) has led to concurrent increase in C." | ( Ahmed, NH; Behera, HS; Satpathy, G, 2017) |
| "trachomatis Plus RG PCR, Qiagen) using molecular diagnostics quality control standards and clinical samples." | ( Burton, MJ; Butcher, R; Derrick, T; Herrera, B; Holland, MJ; Houghton, J; Last, AR; Massae, PA; Ramadhani, A; Roberts, CH, 2017) |
| "Trachoma is targeted for global elimination." | ( Dize, L; Ervin, AM; Gaydos, CA; Mkocha, H; Munoz, B; Quinn, TC; Swenor, B; West, SK, 2017) |
| "Trachoma is chronic kerato conjunctivitis, which is caused by repeated infection with Chlamydia trachomatis bacterium." | ( Kumie, A; Tadesse, B; Worku, A; Yimer, SA, 2017) |
| "Trachoma is the leading infectious cause of blindness in the world and is associated with precarious living conditions in developing countries." | ( Alves da Cunha, AJL; Favacho, J; Freitas, FB; Gomes, STM; Ishak, MOG; Ishak, R; Queiroz, MAF; Vallinoto, ACR, 2018) |
| "Trachoma is the leading infectious cause of blindness worldwide." | ( Astale, T; Ayenew, G; Callahan, EK; Chanyalew, M; Gessese, D; Melak, B; Nash, SD; Nute, AW; Sata, E; Stewart, AEP; Tadesse, Z; Zerihun, M, 2018) |
| "trachomatis DNA." | ( Bayissasse, B; Callahan, EK; Chanyalew, M; Chernet, A; Emerson, PM; Endeshaw, T; Gessese, D; King, JD; Lietman, TM; Melak, B; Moncada, J; Nash, SD; Sata, E; Stewart, AEP; Tadesse, Z; Zerihun, M, 2018) |
| "Trachoma is a public health problem in Guinea." | ( Amon, JJ; Badila, CF; Baldé, MS; Bamba, IF; Géopogui, A; Lamah, L; Ngondi, J; Nieba, C; Reid, SD; Solomon, AW; Tougoue, JJ; Yattara, ML; Zhang, Y, 2018) |
| "Ocular Chlamydia trachomatis infection, the causative agent for trachoma, is responsible for 1." | ( West, SK; Wolle, MA, 2019) |
| "Globally, trachoma is the leading cause of blindness and is responsible for about 1." | ( Fernandez, R; Lapkin, S; Matchawe, C; Tanywe, AC, 2019) |
| "trachomatis infection and clinical signs three- and six- months post treatment relative to three pre-treatment time-points." | ( Bailey, RL; Burton, MJ; Derrick, T; Holland, MJ; Mabey, DCW; Macleod, D; Makupa, W; Malisa, A; Massae, P; Mbuya, K; Mtuy, T; Ramadhani, AM; Roberts, CH, 2019) |
| "C." | ( Bailey, RL; Burton, MJ; Derrick, T; Holland, MJ; Mabey, DCW; Macleod, D; Makupa, W; Malisa, A; Massae, P; Mbuya, K; Mtuy, T; Ramadhani, AM; Roberts, CH, 2019) |
| "trachomatis infection and inflammatory disease signs were significantly reduced three- and six- months post-mass drug administration (MDA)." | ( Bailey, RL; Burton, MJ; Derrick, T; Holland, MJ; Mabey, DCW; Macleod, D; Makupa, W; Malisa, A; Massae, P; Mbuya, K; Mtuy, T; Ramadhani, AM; Roberts, CH, 2019) |
| "Trachoma is the leading infectious cause of blindness." | ( Alemayehu, W; Biran, A; Burton, MJ; Greenland, K; Sarah, V; Sommers, K; White, S, 2019) |
| "trachomatis prevalence, organism load, and circulating strains at baseline and one-year post-MDA in The Gambia and Senegal." | ( Andreasen, AA; Bailey, RL; Christerson, L; Grundy, C; Harding-Esch, EM; Herrmann, B; Holland, MJ; Jeffries, D; Mabey, DCW; Molina-Gonzalez, S; Pickering, H; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2019) |
| "trachomatis infection and organism load (ompA copy number), and ompA and multi-locus sequence typing (MLST) was performed." | ( Andreasen, AA; Bailey, RL; Christerson, L; Grundy, C; Harding-Esch, EM; Herrmann, B; Holland, MJ; Jeffries, D; Mabey, DCW; Molina-Gonzalez, S; Pickering, H; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2019) |
| "trachomatis prevalence increased from 3." | ( Andreasen, AA; Bailey, RL; Christerson, L; Grundy, C; Harding-Esch, EM; Herrmann, B; Holland, MJ; Jeffries, D; Mabey, DCW; Molina-Gonzalez, S; Pickering, H; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2019) |
| "trachomatis infection, with heterogeneity observed between villages studied." | ( Andreasen, AA; Bailey, RL; Christerson, L; Grundy, C; Harding-Esch, EM; Herrmann, B; Holland, MJ; Jeffries, D; Mabey, DCW; Molina-Gonzalez, S; Pickering, H; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2019) |
| "Ocular C." | ( Alkhidir, AAI; Breuer, J; El Hussain, KMK; Elemam, AE; Elhag, WI; Holland, MJ; Ournasseir, MEH; Pickering, H; Williams, CA, 2019) |
| "trachomatis isolates to improve understanding of pathogen diversity in North-East Africa and examine for genomic variation specific to Sudan, possibly related to the persistence of trachoma in surveyed communities." | ( Alkhidir, AAI; Breuer, J; El Hussain, KMK; Elemam, AE; Elhag, WI; Holland, MJ; Ournasseir, MEH; Pickering, H; Williams, CA, 2019) |
| "trachomatis isolates." | ( Alkhidir, AAI; Breuer, J; El Hussain, KMK; Elemam, AE; Elhag, WI; Holland, MJ; Ournasseir, MEH; Pickering, H; Williams, CA, 2019) |
| "trachomatis suggests minimal transmission between and slow diversification within trachoma-endemic communities." | ( Alkhidir, AAI; Breuer, J; El Hussain, KMK; Elemam, AE; Elhag, WI; Holland, MJ; Ournasseir, MEH; Pickering, H; Williams, CA, 2019) |
| "Trachoma is the leading infectious cause of blindness globally." | ( Altherr, FM; Astale, T; Ayenew, G; Callahan, EK; Chanyalew, M; Gashaw, B; Gessese, D; Melak, B; Nash, SD; Nute, AW; Sata, E; Stewart, AEP; Tadesse, Z; Waller, LA; Zerihun, M, 2019) |
| "Trachoma is a contagious infection of the eye by specific strains of the bacteria Chlamydia trachomatis." | ( Bekuma, TT; Desalegn Waktole, Z; Gaddisa, S; Markos Cafo, J; Mosisa Kebebew, G; Wirtu, D, 2019) |
| "trachomatis DNA." | ( Gaydos, C; Mkocha, H; Munoz, B; Nanji, AA; Quinn, TC; West, SK, 2019) |
| "trachomatis DNA." | ( Gaydos, C; Mkocha, H; Munoz, B; Nanji, AA; Quinn, TC; West, SK, 2019) |
| "C." | ( Gaydos, C; Mkocha, H; Munoz, B; Nanji, AA; Quinn, TC; West, SK, 2019) |
| "trachomatis infection in nonhuman primates." | ( Chen, C; Chen, H; Chen, L; Li, C; Lu, C; Peng, B; Sun, Z; Zhong, G; Zhu, C, 2020) |
| "trachomatis organisms, and analyzed by C." | ( Chen, C; Chen, H; Chen, L; Li, C; Lu, C; Peng, B; Sun, Z; Zhong, G; Zhu, C, 2020) |
| "trachomatis antigens." | ( Chen, C; Chen, H; Chen, L; Li, C; Lu, C; Peng, B; Sun, Z; Zhong, G; Zhu, C, 2020) |
| "Trachoma is a contagious infection of the eye." | ( Gebreyesus, A; Reda, G; Yemane, D, 2020) |
| "trachomatis infection data were collected for 1613 children aged 0-9 years in 12 Senegalese villages as part of a cross-sectional trachoma prevalence study." | ( Andreasen, AA; Bailey, RL; Butcher, RMR; Harding-Esch, EM; Holland, MJ; Mabey, DCW; Molina-Gonzalez, S; Sarr, B; Schémann, JF; Sissoko, M, 2020) |
| "trachomatis (primary outcome), TF and other clinical signs of trachoma, and serologic markers of trachoma after 3 years." | ( Amza, A; Arnold, BF; Arzika, AM; Austin, A; Kadri, B; Lebas, E; Lietman, TM; Nassirou, B; Nyatigo, F; Oldenburg, CE, 2021) |
| "trachomatis infection would benefit from a simple blood test that could be integrated with other public health programs." | ( Bethea, D; Callahan, EK; Chernet, A; Gwyn, S; Haile, M; Laurent, C; Martin, DL; Nash, SD; Nute, AW; Sata, E; Tadesse, Z; Zeru, T, 2021) |
| "Ocular surface C." | ( Ayele, B; Chen, C; Doan, T; Emerson, PM; Gebre, T; Hinterwirth, A; Keenan, JD; Lietman, TM; Porco, TC; Ruder, K; Zerihun, M; Zhong, L; Zhou, Z, 2022) |
| "trachomatis and 3 Neisseria species in communities treated with azithromycin." | ( Ayele, B; Chen, C; Doan, T; Emerson, PM; Gebre, T; Hinterwirth, A; Keenan, JD; Lietman, TM; Porco, TC; Ruder, K; Zerihun, M; Zhong, L; Zhou, Z, 2022) |
| "The C." | ( Astale, T; Ayele, Z; Chernet, A; Gessese, D; Haile, M; Jensen, KA; Kelly Callahan, E; Melak, B; Nash, SD; Nute, AW; Sata, E; Tadesse, Z; Zerihun, M; Zeru, T, 2021) |
| "Trachoma is an infectious disease characterized by repeated exposures to Chlamydia trachomatis (Ct) that may ultimately lead to blindness." | ( Aragie, S; Arnold, BF; Gwyn, S; Haile, M; Keenan, JD; Lietman, TM; Martin, DL; Nash, SD; Sturrock, HJW; Tadesse, Z; Tedijanto, C; Wittberg, DM; Zeru, T, 2022) |
| "trachomatis prevalence was 34." | ( Apadinuwe, SC; Bakhtiari, A; Butcher, R; Cama, A; Catlett, B; Cunningham, P; Garabwan, C; Gwyn, S; Harding-Esch, EM; Hillgrove, T; Kaldor, JM; Lambert, SB; Lynch, KD; Martin, D; Solomon, AW; Starr, M; Vaz Nery, S; Ware, RS; Webster, S, 2022) |
| "trachomatis transmission among children present a high risk of ocular damage due to trachoma." | ( Apadinuwe, SC; Bakhtiari, A; Butcher, R; Cama, A; Catlett, B; Cunningham, P; Garabwan, C; Gwyn, S; Harding-Esch, EM; Hillgrove, T; Kaldor, JM; Lambert, SB; Lynch, KD; Martin, D; Solomon, AW; Starr, M; Vaz Nery, S; Ware, RS; Webster, S, 2022) |
| "Trachoma is a predominant neglected disease in Ethiopia, and there is a 40." | ( Adem, A; Bekele, D; Feyisa, T; Nugusu, F; Tura, B, 2022) |
| "Trachoma is the leading infectious cause of blindness." | ( Abdala, M; Al-Khateeb, TQ; Amza, A; Baayenda, G; Badiane, MD; Bakhtiari, A; Batcho, WE; Bella, AL; Bio Issifou, AA; Bobo Barkesa, S; Bucumi, V; Elshafie, BE; Epee, E; Freeman, MC; Gower, EW; Harding-Esch, EM; Kabona, GE; Kadri, B; Kaitaba, O; Kalua, KM; Keil, AP; Masika, MP; Massangaie, ME; Minnih, AO; Mpyet, CD; Mwale, C; Nassirou, B; Olobio, N; Sanha, S; Seife Gebretsadik, F; Simon, A; Solomon, AW; Sullivan, KM; Westreich, D, 2023) |
| "Trachoma is a leading cause of preventable blindness." | ( Hussen, MS; Munaw, MB; Shobiso, MG; Tilahun, MM, 2023) |
| "trachomatis antigen Pgp3, seroprevalence in 1-9-year-olds was 30." | ( Bakhtiari, A; Butcher, R; Cama, A; Goodhew, EB; Guagliardo, SAJ; Gwyn, SE; Harding-Esch, EM; Jimenez, C; Martin, DL; Mpyet, CD; Solomon, AW; Taoaba, R; Tekeraoi, R; Tun, K; Wickens, K, 2023) |
| "Trachoma is the chief cause of preventable blindness worldwide and has been earmarked for elimination as a public health problem by 2030." | ( Asebe, HA; Asgedom, YS; Asmare, ZA; Fente, BM; Kase, BF; Lombebo, AA; Mare, KU; Sabo, KG; Seifu, BL; Shibeshi, AH; Tebeje, TM; Teshale, AB, 2023) |
| "Trachoma is a neglected tropical disease caused by ocular infection with Chlamydia trachomatis, where repeated infections and chronic inflammation can ultimately result in scarring, trichiasis and blindness." | ( Bailey, R; Barton, A; Burton, MJ; Derrick, T; Faal, N; Harte, A; Holland, MJ; Joof, H; Mabey, DC; Mafuru, E; Makalo, P; Malissa, A; Massae, P; Mtuy, T; Pickering, H; Ramadhani, A; Sillah, A, 2023) |
| "trachomatis infection, possibly due to a positive feedback loop inducing immune activation." | ( Bailey, R; Barton, A; Burton, MJ; Derrick, T; Faal, N; Harte, A; Holland, MJ; Joof, H; Mabey, DC; Mafuru, E; Makalo, P; Malissa, A; Massae, P; Mtuy, T; Pickering, H; Ramadhani, A; Sillah, A, 2023) |
| "Trachoma is the world's most frequent cause of blindness from an infectious agent." | ( Downs, P; Jeyam, A; Kebede, F; Selby, R; Tate, A, 2023) |
| Excerpt | Reference |
|---|
| "A controlled chemotherapy trial of trachoma was carried out in a Tunisian oasis among schoolchildren with active disease." | ( Daghfous, T; Dawson, CR; Hoshiwara, I; Messadi, M; Schachter, J; Vastine, DW, 1975) |
| "The detection of Chlamydia trachomatis by direct immunofluorescence (IF) using a conjugated monoclonal antibody to its principal outer membrane protein was compared with isolation in cycloheximide-treated McCoy cells." | ( Booth-Mason, S; Mabey, DC, 1986) |
| "In communities with endemic blinding trachoma, mass (or "blanket") treatment with a topically applied tetracycline derivative is a standard control measure." | ( Briones, O; Chadgrah, F; Daghfous, T; Dawson, CR; Hoshiwara, T; Messadi, M; Schachter, J; Triki, F; Whitcher, J; Yoneda, C, 1981) |
| "In patients with scarring trachoma, the treatment did not significantly reduce the inclusion count." | ( Babikir, HE; Elhassan, AE; Fröman, G; Mahmoud, EA; Mårdh, PA, 1994) |
| "In order to optimize the trachoma treatment duration, we carried out a prospective study to observe the disease course over a long period of treatment by a 1% oxytetracycline (chlorhydrate) suspension." | ( Bagayogo, C; Castan, R; Huguet, P; Peyramaure, F; Resnikoff, S, 1994) |
| "Clinical trachoma, and microbiologic evidence of chlamydia, were assessed at baseline, 2 and 4 weeks into mass treatment, and 4 weeks after treatment stopped." | ( Bobo, L; Lynch, M; Mkocha, H; Mmbaga, BB; Muñoz, B; Quinn, TC; Viscidi, R; West, S, 1993) |
| "Risk factors for constant, severe trachoma were identified in a group of children enrolled in a longitudinal study in Kongwa, Tanzania, where villages were randomized in a clinical trial of mass treatment and a behavior modification campaign." | ( Kayongoya, A; Lynch, M; Mmbaga, BB; Muñoz, B; Taylor, HR; West, SK, 1996) |
| "Risk factors for constant, severe trachoma were identified in a group of children enrolled in a longitudinal study in Kongwa, Tanzania, where villages were randomized in a clinical trial of mass treatment and a behavior modification campaign." | ( Kayongoya, A; Lynch, M; Mmbaga, BB; Muñoz, B; Taylor, HR; West, SK, 1996) |
| "For children with trachoma, rates of carriage of pneumococci immediately before treatment with azithromycin and 2-3 weeks, 2 months, and 6 months after treatment were 68% (54 of 79), 29% (11 of 38), 78% (29 of 37), and 87% (34 of 39), respectively." | ( Currie, BJ; Gratten, M; Laming, AC; Leach, AJ; Mathews, JD; Mayo, M; Shelby-James, TM, 1997) |
| "Programmes to prevent blindness due to trachoma are based on community-wide treatment with topical tetracycline." | ( Bailey, R; Bobo, L; Dawson, CR; Faal, H; Mabey, D; Mkocha, H; Quinn, TC; Sallam, S; Schachter, J; Sheta, A; Vitale, S; West, SK, 1999) |
| "Change in trachoma status was determined from baseline to one month post treatment." | ( Lynch, M; O'Connor, J; Vitale, S; West, S, 1999) |
| "Azithromycin treatment for trachoma had favorable short term effects on childhood morbidity in rural Gambian villages, particularly in the high malaria transmission season, and adverse effects were not a problem." | ( Bailey, R; Glasgow, KW; Mabey, DC; Sadiq, ST; Whitty, CJ, 1999) |
| "Repeated mass treatment of trachoma endemic areas with oral azithromycin will have an effect on bacterial flora." | ( Cevallos, V; Chern, KC; Chern, L; Dhami, HL; Lietman, TM; Shrestha, SK; Tiwari, P; Whitcher, JP, 1999) |
| "Community control of trachoma as a blinding disease is based on the SAFE strategy of Surgery, Antibiotic therapy, Facial cleanliness and Environmental improvement." | ( Bailey, RL; Cairncross, S; Emerson, PM; Mabey, DC, 2000) |
| "To ascertain the prevalence of acute trachoma as a supposed endemic disease among infants in the Saharan refugee camps of Tindouf (Algeria) and to evaluate the efficacy of treatment with a single dose of azithromycin." | ( Alió, JL; Ferrer, C; Javaloy, J; Vidal, MT, 2003) |
| "National programs for trachoma control are implementing mass treatment programs in which azithromycin is used as part of the control strategy." | ( Bailey, R; Barwick, R; Burton, M; Foster, A; Mabey, D; Muñoz, B; Solomon, AW; West, SK; Zingeser, J, 2003) |
| "Clinically active trachoma is not always a reliable marker of infection, particularly in teenagers and after treatment." | ( Bassem, A; Bird, M; Dawson, CR; Lietman, TM; Miao, Y; Osman, A; Schachter, JS; Shama, A, 2003) |
| "Data were gathered on risk factors for trachoma, socioeconomic status, and the perceived effect of the initial azithromycin treatment." | ( Frick, KD; Lynch, M; Mkocha, HA; Munoz, B; West, S, 2003) |
| "As those at greatest risk of active trachoma indicated the lowest willingness to pay, imposing a cost recovery fee for azithromycin treatment would likely reduce coverage and could prevent control of the disease at the community level." | ( Frick, KD; Lynch, M; Mkocha, HA; Munoz, B; West, S, 2003) |
| "Although trachomatous blindness is untreatable, it is eminently possible to prevent and the World Health Organization promotes the use of the SAFE strategy (surgery to treat end-stage disease, antibiotics to reduce the reservoir of infection, facial cleanliness, and environmental improvement to reduce transmission of C trachomatis) for this purpose." | ( Buchan, J; Foster, A; Kuper, H; Mabey, D; Solomon, AW; Zondervan, M, 2003) |
| "Even if the number of cases of trachoma in the world is now 6-fold lower than twenty years ago, still 83 millions of patients are affected by active trachoma, leading to the estimation that 490 millions of people should be treated in a curative or a preventive way." | ( Labetoulle, M; Raymond, J, 2005) |
| "In a community of Tanzania where trachoma is endemic, we cultured conjunctival swabs from all residents who had active trachoma and were PCR positive for ocular Chlamydia trachomatis, both before (43 isolates) and 2 months after (9 isolates) mass antibiotic treatment." | ( Foster, A; Mabey, DC; Massae, PA; Mohammed, Z; Peeling, RW; Shao, JF; Solomon, AW, 2005) |
| "Active trachoma and swab samples of the conjunctiva were assessed at baseline and at 2, 6, 12, and 18 months after treatment." | ( Broman, AT; Duncan, DD; Munoz, B; Shum, K; West, SK, 2006) |
| "Infection with C trachomatis did not differ between groups at 6 months post-treatment (9%vs 7%, p=0." | ( Bailey, R; Emerson, PM; Mabey, D; McHiwa, W; Mkocha, H; Munoz, B; West, SK, 2006) |
| "In active trachoma, azithromycin eye drops twice daily for 2 or 3 days are as efficient as the WHO's reference treatment and represent an innovative alternative to oral azithromycin." | ( Afghani, T; Bourcier, T; Cochereau, I; Delval, L; Goepogui, A; Goldschmidt, P; Pouliquen, P; Robert, PY, 2007) |
| "In mesoendemic trachoma areas, targeted treatment to all children under 11 years of age and women between 15 and 50 (strategy II) was as effective as indiscriminate mass distribution (strategy I) and more effective than treatment targeted to inhabitants of households where at least one child had active trachoma diagnosed (strategy III)." | ( Dembele, M; Diallo, I; Guinot, C; Malvy, D; Schémann, JF; Traore, A; Traore, L; Vinard, P; Zefack, G, 2007) |
| "Active trachoma was found in a high percentage of children in Al-Jawf, Mareb and Shabwah governorates and the SAFE strategy (Surgery, Antibiotic treatment, Facial cleanliness, Environmental improvement) should be directed toward these governorates." | ( Al-Jabal, MH; Al-Khatib, TK; Al-Kuhlany, AM; Hamid, AS; Raja'a, YA, 2006) |
| "A stochastic model of trachoma transmission was constructed, using the parameters with the maximum likelihood of obtaining results observed from studies in Tanzania (with 16% infection in children pre-treatment), The Gambia (9%), and Ethiopia (64%)." | ( Bailey, RL; Burton, MJ; Harding-Esch, E; Holland, MJ; Keenan, JD; Lietman, TM; Mabey, D; Porco, TC; Ray, KJ; Solomon, AW, 2009) |
| "Clinical trachoma activity in children aged 1 to 5 years decreased from 78% and 83% in the 2 villages before treatment to 17% and 24% at 42 months." | ( Alemayehu, W; Biebesheimer, JB; Gaynor, BD; Hong, KC; House, J; Keenan, J; Lakew, T; Lietman, TM; Moncada, J; Rogér, A; Schachter, J; Zhou, Z, 2009) |
| "In a region with hyperendemic trachoma, conjunctival examination was a useful indicator of the prevalence of chlamydial infection before treatments, less useful during mass treatments, but regained utility by one year after treatments had stopped." | ( Acharya, NR; Alemayehu, W; Gaynor, BD; House, JI; Keenan, JD; Lakew, T; Lietman, TM; Melese, M; Porco, TC; Ray, KJ; Whitcher, JP; Yi, E; Zhou, Z, 2010) |
| "Mass treatment to trachoma endemic communities is a critical part of the World Health Organization SAFE strategy." | ( Bailey, RL; Edwards, T; Harding-Esch, EM; Mabey, DC; Mkocha, H; Munoz, B; Sillah, A; Ssemanda, EN; Stare, D; West, SK, 2010) |
| "Active trachoma mass treatment with azithromycin 1." | ( Amza, A; Bella-Assumpta, L; Bensaid, P; Einterz, E; Goldschmidt, P; Huguet, P; Olmiere, C, 2010) |
| "As part of its strategy to eliminate trachoma, the World Health Organization recommends annual mass antibiotic treatment for at least 3 years with an 80% population coverage target." | ( Bailey, R; Gaydos, C; Harding-Esch, E; Holland, M; Mabey, D; Munoz, B; Stare, D; West, S, 2011) |
| "Therapy for trachoma had barely advanced from the measures used by the ancient Egyptian, Greek, and Roman physicians." | ( Feibel, RM, 2011) |
| "We determined the prevalence of trachoma and infection with Chlamydia trachomatis in communities after 3-7 years of annual mass treatment in Tanzania." | ( Gaydos, CA; Mkocha, H; Munoz, B; Quinn, TC; West, SK, 2011) |
| "Country programs in trachoma-endemic regions must realistically expect that several years of annual mass treatment may be necessary to eliminate trachoma." | ( Gaydos, CA; Mkocha, H; Munoz, B; Quinn, TC; West, SK, 2011) |
| "Mass treatment with azithromycin for trachoma endemic communities typically excludes infants under age 6 months, whose parents are provided with tubes of tetracycline to administer daily over 4 to 6 weeks." | ( Gaydos, C; Mkocha, H; Munoz, B; Quinn, TC; Stare, D; West, SK, 2011) |
| "The clinical signs of active trachoma are often present in the absence of ocular Chlamydia trachomatis infection in low prevalence and mass treated settings." | ( Andreasen, AA; Bailey, RL; Edwards, T; Harding, EF; Harding-Esch, EM; Holland, MJ; Mabey, DC; Molina, S; Roberts, Ch; Sarr, B; Sarr, I; Schémann, JF; Sillah, A, 2011) |
| "Twelve trachoma-hyperendemic communities were treated with 3 annual mass azithromycin distributions." | ( Ayele, B; Emerson, PM; Gaynor, BD; Gebre, T; Keenan, JD; Lietman, TM; McCulloch, CE; Moncada, J; Porco, TC; Schachter, J; Stoller, NE; Zhou, Z, 2012) |
| "Although trachoma control programs frequently use the World Health Organization (WHO) simplified grading system for trachoma to monitor the clinical response after repeated mass azithromycin treatments, the programmatic relevance of this evaluation after multiple rounds of antibiotic treatments is unclear." | ( Ayele, B; Emerson, PM; Gaynor, BD; Gebre, T; Keenan, JD; Lietman, TM; McCulloch, CE; Moncada, J; Porco, TC; Schachter, J; See, CW; Stoller, NE, 2012) |
| "Mass treatment for trachoma using a single dose of oral azithromycin was provided in 4 of the 8 communities where trachoma prevalence was ." | ( Coles, CL; Levens, J; Mkocha, H; Munoz, B; Seidman, JC; West, S, 2012) |
| "In areas with highly prevalent trachoma treated with multiple rounds of mass azithromycin, trachoma programs could consider continuing mass azithromycin treatments in households that have missed prior mass antibiotic treatments, in households with clinically active trachoma, and in larger communities." | ( Ayele, B; Emerson, PM; Gaynor, BD; Gebre, T; House, JI; Keenan, JD; Moncada, J; Porco, TC; Schachter, J; Stoller, NE; Zhou, Z, 2011) |
| "For children with severe trachoma, a randomized controlled trial of 2-day versus 1-day treatment may be warranted." | ( Campbell, JP; Mkocha, H; Munoz, B; West, SK, 2012) |
| "In children with trachomatous inflammation, 3-day treatment with azithromycin 1." | ( Garnock-Jones, KP, 2012) |
| "Though trachoma can be treated with antibiotics (active trachoma) or surgery (trachomatous trichiasis), it is still endemic in most parts of Ethiopia." | ( Ejigu, M; Gelaw, Y; Ilako, DR; Kariuki, MM, 2013) |
| "To eliminate blinding trachoma, the World Health Organization emphasizes implementing the SAFE strategy, which includes annual mass drug administration (MDA) with azithromycin to the whole population of endemic districts." | ( Admassu Ayele, F; Adugna, M; Ayalew, F; Cromwell, EA; Damte, M; Emerson, PM; Endashaw, T; Gebre, T; Gebregzabher, T; Gessesse, D; Haileysus, G; Karie, A; King, JD; King, MR; Melak, B; Mosher, AW; Mulualem, A; Ngondi, JM; Odermatt, P; Stoller, NE; Tadesse, Z; Teferi, T; Utzinger, J; Worku, A; Zerihun, M, 2014) |
| "Antibody responses to trachoma antigens declined significantly six months after drug treatment for most age groups." | ( Dize, L; Gaydos, C; Goodhew, EB; Lammie, PJ; Martin, DL; Mkocha, H; Morgan, SM; Munoz, B; Switzer, AJ; West, SK; Wiegand, RE, 2014) |
| "Mass administration of azithromycin for trachoma has been shown to reduce malarial parasitemia." | ( Ackley, SF; Amza, A; Gao, D; Kadri, B; Lietman, TM; Liu, F; Nassirou, B; Porco, TC; Sippl-Swezey, N, 2014) |
| "In 2009, trachoma prevalence was 14%, but through screening, treatment and health promotion, rates had fallen to 4% in 2012." | ( Anjou, MD; Atkinson, JR; Boudville, AI; Lange, FD; Stanford, EE, 2014) |
| "We used the International Trachoma Initiative's prevalence and treatment database." | ( Emerson, PM; Gelderblom, HC; Haddad, D; Jimenez, V; Mann Flueckiger, R, 2015) |
| "Both yaws and trachoma--which is earmarked for elimination by 2020 using a strategy that includes mass treatment with 20 mg/kg azithromycin--are endemic in the Pacific, raising the possibility of an integrated approach to disease control." | ( Bottomley, C; Chi, KH; Dalipanda, T; Kilua, G; Mabey, DC; Marks, M; Pillay, A; Puiahi, E; Sokana, O; Solomon, AW; Vahi, V, 2015) |
| "Though trachoma can be treated with antibiotic it is still endemic in most part of Ethiopia." | ( Berhe, R; Gedefaw, M; Nigusie, A, 2015) |
| "Mass drug administration (MDA) for trachoma control is administered based on the population prevalence of the clinical sign of trachomatis inflammation - follicular (TF)." | ( Bailey, RL; Cassama, E; Derrick, T; Holland, MJ; Last, AR; Markham-David, R; Marks, M; Nabicassa, M, 2016) |
| "Despite some success in controlling trachoma with repeated mass drug administration (MDA), some hyperendemic regions are not responding as fast as anticipated." | ( Burton, MJ; Gambhir, M; Pinsent, A, 2016) |
| "We estimated the change in trachoma prevalence between sequential pairs of years and across multiple years according to treatment strategy using random-effects meta-analyses." | ( Cowling, C; Hayen, A; Kaldor, JM; Lambert, S; Liu, B; Mak, DB; Taylor, H; Watt, G, 2016) |
| "Prevention of Trachoma, the leading cause of infectious blindness, requires community treatment assistants (CTAs) to perform mass drug administration (MDA) of azithromycin." | ( Jenson, A; Mkocha, H; Munoz, B; Roter, DL; West, S, 2018) |
| "The antibiotic treatment of people with trachoma helps to prevent transmission the disease in a community." | ( Asfaw, S; Gebregergs, GB; Gigar, G; Kidane, A; Meresa, B; Mitiku, M; Mulugeta, A; Yemane, D, 2018) |
| "We undertook population-based trachoma surveys in 18 evaluation units of the 8 treated districts, at least 6 months after the MDA." | ( Bailey, RL; Bakhtiari, A; Chinyanya, D; Chisambi, A; Emerson, PM; Kalua, K; Masika, M; Solomon, AW; Willis, R, 2018) |
| "Mass drug administration (MDA) for trachoma control using azithromycin has generated concern for the development of resistant organisms." | ( Ansah, D; Bloch, EM; Coles, CL; Lietman, T; Munoz, B; Weaver, J; West, SK, 2019) |
| "Regions with low prevalence of active trachoma may have little if any ocular chlamydia, and, thus, may not benefit from azithromycin treatment." | ( Amza, A; Aragie, S; de Hostos Barth, A; Godwin, WW; Landskroner, E; Lietman, TM; Mahmud, H; O'Brien, KS; Oldenburg, CE, 2021) |
| "Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation-follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin." | ( Bethea, D; Callahan, EK; Chernet, A; Gwyn, S; Haile, M; Laurent, C; Martin, DL; Nash, SD; Nute, AW; Sata, E; Tadesse, Z; Zeru, T, 2021) |
| "The International Trachoma Initiative (ITI) provides azithromycin for mass drug administration (MDA) to eliminate trachoma as a public health problem." | ( Addiss, DG; Alemu, M; Ciciriello, AM; Emerson, PM; Gebre, T; Hooper, PJ; Kebede, F; Kiflu, G; LaCon, G; Seid, M; Seife, F; Sormolo, MJ; Tadesse, G; Teferi, T; West, SK, 2022) |
| "Persistent and recrudescent trachoma in evaluation units (EUs) were examined for whether AZM MDA in EUs was accompanied by IVM MDA, and whether co-administration was associated with greater likelihood of trachoma control." | ( Downs, P; Jeyam, A; Kebede, F; Selby, R; Tate, A, 2023) |